PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First new treatment for asthma attacks in 50 years

2024-11-28
(Press-News.org) An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

The findings, published today in The Lancet Respiratory Medicine, could be “game-changing” for millions of people with asthma and COPD around the world, scientists say.

Asthma attacks and COPD flare-ups (also called exacerbations) can be deadly. Every day in the UK four people with asthma and 85 people with COPD will tragically die. Both conditions are also very common, in the UK someone has an asthma attack every 10 seconds. Asthma and COPD costs the NHS £5.9B a year. 

The type of symptom flare-up the injection treats are called ‘eosinophilic exacerbations’ and involve symptoms such as wheezing, coughing and chest tightness due to inflammation resulting from high amounts of eosinophils (a type of white blood cell). Eosinophilic exacerbations make up to 30% of COPD flare-ups and almost 50% of asthma attacks. They can become more frequent as the disease progresses, leading to irreversible lung damage in some cases.

Treatment at the point of an exacerbation for this type of asthma has barely changed for over fifty years, with steroid drugs being the mainstay of medication. Steroids such as prednisolone can reduce inflammation in the lungs but have severe side-effects such as diabetes and osteoporosis. Furthermore, many patients ‘fail’ treatment and need repeated courses of steroids, re-hospitalisation or die within 90 days.

Results from the phase two clinical trial ABRA study, led by scientists from King’s College London and sponsored by the University of Oxford, show a drug already available can be re-purposed in emergency settings to reduce the need for further treatment and hospitalisations. The multi-centre trial was conducted at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust.

Benralizamab is a monoclonal antibody which targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

The study investigators randomised people at high risk of an asthma or COPD attack into three groups, one receiving benralizumab injection and dummy tablets, one receiving standard of care (prednisolone 30mg daily for five days) and dummy injection and the third group receiving both benralizumab injection and standard of care. As a double-blind, double-dummy, active-comparator placebo-controlled trial, neither the people in the study, or the study investigators knew which study arm or treatment they were given.

After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab. After ninety days, there were four times fewer people in the benralizumab group that failed treatment compared to standard of care with prednisolone.

Treatment with the benralizumab injection took longer to fail, meaning fewer episodes to see a doctor or go to hospital. There was also an improvement in the quality of life for people with asthma and COPD.

Lead investigator of the trial Professor Mona Bafadhel from King’s College London said: “This could be a game-changer for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in fifty years despite causing 3.8 million deaths worldwide a year combined.

“Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation - to show that it’s more effective than steroid tablets which is the only treatment currently available. The big advance in the ABRA study is the finding that targeted therapy works in asthma and COPD attacks. Instead of giving everyone the same treatment, we found targeting the highest risk patients with very targeted treatment, with the right level of inflammation was much better than guessing what treatment they needed.”

The benralizumab injection was administered by healthcare professionals in the study but can be potentially administered safely at home, in the GP practice, or in the Emergency Department. Benralizumab was safe in the study and similar in safety to many past studies.

Professor Mona Bafadhel said, “We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future, ultimately improving the health for over a billion people living with asthma and COPD across the world.”

Dr Sanjay Ramakrishnan, Clinical Senior Lecturer at the University of Western Australia, who is the first author of the ABRA trial and started the work while at the University of Oxford, said: “Our study shows massive promise for asthma and COPD treatment. COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out.

“The ABRA trial was only possible with collaboration between the NHS and universities and shows how this close relationship can innovate healthcare and improve people’s lives.”

Geoffrey Pointing, 77 from Banbury, who took part in the study, said: “Honestly, when you're having a flare up, it's very difficult to tell anybody how you feel - you can hardly breathe. Anything that takes that away and gives you back a normal life is what you want. But on the injections, it's fantastic. I didn't get any side effects like I used to with the steroid tablets. I used to never sleep well the first night of taking steroids, but the first day on the study, I could sleep that first night, and I was able to carry on with my life without problems. I want to add that I'm just grateful I took part and that the everyone involved in the ABRA study are trying to give me a better life.”

Dr Samantha Walker, Director of Research and Innovation, at Asthma + Lung UK, said: “It’s great news for people with lung conditions that a potential alternative to giving steroid tablets has been found to treat asthma attacks and chronic obstructive pulmonary disease (COPD) exacerbations. But it’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is. 

“Every four minutes in the UK, someone dies from a lung condition. Thousands more live with the terror of struggling to breathe every day. With your help, we're fighting for more life-changing, life-saving research to transform the future for everyone living with breathing problems. Together, we’ll make sure that families everywhere never face a lung condition without the best treatment and care.  

“Our vision is a world where everyone has healthy lungs. We can only get there with your help.” 

This research was conducted with support from AstraZeneca UK Limited.

The paper, titled Monoclonal antibody better than standard treatment for some types of asthma attacks and COPD flare-ups, phase II clinical trial results suggest, is published in The Lancet Respiratory Medicine.

ENDS

END


ELSE PRESS RELEASES FROM THIS DATE:

Certain HRT tablets linked to increased heart disease and blood clot risk

2024-11-28
Certain hormone replacement therapy (HRT) tablets containing both oestrogen and progestogen are associated with a higher risk of heart disease and rare but serious blood clots known as venous thromboembolism (VTE) in women around the age of menopause, finds a study from Sweden published by The BMJ today. Another HRT tablet called tibolone was associated with an increased risk of heart disease, heart attack and stroke, but not blood clots, “highlighting the diverse effects of different hormone combinations and administration methods on the risk of cardiovascular disease,” say the researchers. HRT is used to relieve menopausal ...

Talking therapy and rehabilitation probably improve long covid symptoms, but effects modest

2024-11-28
Cognitive behavioural therapy (CBT) and a programme of physical and mental rehabilitation probably improve symptoms of long covid, but the effects are modest, finds a review of the latest evidence published by The BMJ today. Intermittent aerobic exercise also probably improves physical function compared with continuous aerobic exercise. But the researchers found no compelling evidence to support the effectiveness of other interventions, including certain drugs, dietary supplements, inspiratory muscle training, transcranial ...

Ban medical research with links to the fossil fuel industry, say experts

2024-11-28
An investigation published by The BMJ today reveals the extent of fossil fuel industry involvement in medical research, leading to fresh calls for academics and publishing companies to cut ties with companies. An analysis by journalists Hristio Boytchev, Natalie Widmann and Simon Wörpel found that over the past six years, more than 180 medical articles have acknowledged fossil fuel industry funding, and an additional 1000 articles feature authors who worked for a fossil fuel company or related organisation. While many studies don’t have an obvious link with fossil fuel industry interests, experts told The BMJ that publishing research ...

Different menopausal hormone treatments pose different risks

Different menopausal hormone treatments pose different risks
2024-11-28
Researchers at Uppsala University have analysed the effects of seven different hormone treatments for menopausal symptoms on the risk of blood clots, stroke and heart attack. The study, which involved around one million women aged between 50 and 58, shows that the risks differ depending on the active substance and how the medicine is taken. Published in the scientific journal BMJ, this is the largest and most comprehensive study of currently prescribed hormonal substances in the world. “There is concern among women that menopausal hormone therapy increases the risk of cardiovascular disease. This concern is based on older studies conducted more than ...

Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL

2024-11-27
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center. The findings, published today in the New England Journal of Medicine, ...

Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention

Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention
2024-11-27
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor’s visits every three months and – most importantly – consistency.  These daily oral antiretrovirals, more commonly referred to as PrEP (pre-exposure prophylaxis), such as Truvada®, are extremely effective at HIV prevention, but only if they are taken daily as directed. Truvada’s efficacy is greatly compromised when taken inconsistently.  However, results from a recent Gilead-funded clinical trial (Purpose-2) led by physicians at Emory University ...

Discovering the traits of extinct birds

Discovering the traits of extinct birds
2024-11-27
Looking to inform the conservation of critically endangered bird species, University of Utah biologists completed an analysis identifying traits that correlate with all 216 bird extinctions since 1500. Species most likely to go extinct sooner were endemic to islands, lacked the ability to fly, had larger bodies and sharply angled wings, and occupied ecologically specific niches, according to research published this month. While some of these findings mirror previous research on extinct birds, they are the first to correlate bird traits with the timing of ...

Are health care disparities tied to worse outcomes for kids with MS?

2024-11-27
MINNEAPOLIS – People who develop multiple sclerosis (MS) as children and grow up in less advantaged neighborhoods may have a larger volume of inflammation and brain tissue loss on imaging than those who grow up in more advantaged neighborhoods, according to a study published in the November 27, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. MS rarely develops in children. About 5% of people with MS are diagnosed before age 18. In addition to neighborhood location, worse brain imaging outcomes were also seen ...

For those with CTE, family history of mental illness tied to aggression in middle age

2024-11-27
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, NOVEMBER 27, 2024 MINNEAPOLIS – People who have chronic traumatic encephalopathy (CTE) who have a family history of mental illness may have a higher risk of aggression in middle age, according to a study published in the November 27, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. CTE is a neurodegenerative disease associated with repeated head injuries, often seen in athletes and military personnel, that can lead to mood changes and dementia. “This ...

The sound of traffic increases stress and anxiety

The sound of traffic increases stress and anxiety
2024-11-27
Manmade sounds such vehicle traffic can mask the positive impact of nature soundscapes on people’s stress and anxiety, according to a new study published November 27, 2024, in the open-access journal PLOS ONE by Paul Lintott of the University of the West of England, U.K., and Lia Gilmour of the Bat Conservation Trust, U.K. Existing research shows that natural sounds, like birdsong, can lower blood pressure, heart, and respiratory rates, as well as self-reported stress and anxiety. Conversely, anthropogenic soundscapes, like traffic or aircraft noise, are hypothesized to have negative effects on human health and wellbeing in a variety ...

LAST 30 PRESS RELEASES:

2 U-M faculty members elected to National Academy of Inventors

Breakthroughs in cell-penetrating monoclonal antibody therapies

Accelerated aging in young sickle cell patients linked to elevated T-cell p16INK4a

Nanofluidic devices redefining matter manipulation at an unprecedented level

Powering the future together – Public-Private Collaboration for the energy transition in Finland

Exosome-mediated crosstalk in the tumor immune microenvironment: Critical drivers of hepatocellular carcinoma progression

JMIR Aging achieves top ranking, accepted into prestigious science citation indexes

Persistent tobacco smoking from childhood may cause heart damage by the mid-twenties

Smoking tobacco from childhood can cause premature heart damage

Southwest Research Institute seeks contractors worldwide to support Oil Sampling Program

Statistical and engineering approaches to federated learning: Comprehensive benchmarking for healthcare applications

AI can help us choose words more carefully when talking about addiction

Religious people are not more generous – with one exception

PARP inhibition shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in OlympiA trial

BRCA-mutation carriers with a history of early-onset breast cancer may benefit from risk-reducing surgery

Next-generation SERD protects against progression in some patients with advanced breast cancer resistant to standard hormone therapy

Carnegie Mellon University Africa and Challenger Center collaborate to deliver STEM programs

Top five rising star Texas researchers named in 2025 Edith and Peter O’Donnell Awards by TAMEST

Fast, rewritable computing with DNA origami registers

Uncovering the pigments and techniques used to paint the Berlin Wall

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research

Chung-Ang University researchers unveil the biogenesis and role of transfer RNA fragments in cancer progression

Secret of the female orgasm uncovered by psychologists

Breakthrough in zinc-based rechargeable batteries: A safer, sustainable alternative

"Superman" bacteria offer a sustainable boost to chemical production

FunMap reveals a functional network of genes and proteins in human cancer

First full characterization of kidney microbiome unlocks potential to prevent kidney stones

IMDEA Software researchers present MixBuy, a protocol for secure and privacy-preserving digital purchases

Having a good breakfast reduces cardiovascular risk

New study reveals provincial and territorial inequities and inadequacies in access to medications and treatment for cardiovascular conditions in Canada

[Press-News.org] First new treatment for asthma attacks in 50 years